94 related articles for article (PubMed ID: 28992264)
1. Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Okumura T; Ikeda K; Ujihira T; Okamoto K; Horie-Inoue K; Takeda S; Inoue S
J Biochem; 2018 Jan; 163(1):19-29. PubMed ID: 28992264
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Maynadier M; Basile I; Gallud A; Gary-Bobo M; Garcia M
Oncol Rep; 2016 Aug; 36(2):1127-34. PubMed ID: 27373750
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
4. Depletion of proteasome subunit PSMD1 induces cancer cell death via protein ubiquitination and DNA damage, irrespective of p53 status.
Kim MY; Park ER; Cho EH; Park SH; Han CJ; Kim SB; Gu MB; Shin HJ; Lee KH
Sci Rep; 2024 Apr; 14(1):7997. PubMed ID: 38580756
[TBL] [Abstract][Full Text] [Related]
5. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
7. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
8. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
9. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
10. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Somaï S; Chaouat M; Jacob D; Perrot JY; Rostène W; Forgez P; Gompel A
Int J Cancer; 2003 Jul; 105(5):607-12. PubMed ID: 12740907
[TBL] [Abstract][Full Text] [Related]
12. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
13. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
14. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
15. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
Buck MB; Pfizenmaier K; Knabbe C
Mol Endocrinol; 2004 Jul; 18(7):1643-57. PubMed ID: 15056732
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
[TBL] [Abstract][Full Text] [Related]
18. Proteasome 26S subunit, non-ATPase 1 (PSMD1) facilitated the progression of lung adenocarcinoma by the de-ubiquitination and stability of PTEN-induced kinase 1 (PINK1).
Liu L; Liu A; Dong J; Zuo Z; Liu X
Exp Cell Res; 2022 Apr; 413(2):113075. PubMed ID: 35192838
[TBL] [Abstract][Full Text] [Related]
19. Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
Rezano A; Kuwahara K; Yamamoto-Ibusuki M; Kitabatake M; Moolthiya P; Phimsen S; Suda T; Tone S; Yamamoto Y; Iwase H; Sakaguchi N
BMC Cancer; 2013 Dec; 13():562. PubMed ID: 24289229
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
